Locus Cell Co

Locus Cell Co EV/EBIT

The EV/EBIT (Enterprise Value to EBIT) of Locus Cell Co (6891.TWO) as of Oct 17, 2026 is -33.98. In the previous year, EV/EBIT (Enterprise Value to EBIT) was -38.32 — a change of -11.33% (higher).

EV/EBIT

-33.98

YoY

-11.33%

Last updated:

EV/EBIT (Enterprise Value to EBIT) of Locus Cell Co is 2024 -33.98 . EV/EBIT (Enterprise Value to EBIT) of Locus Cell Co was 2023 -38.32 . It decreases by -11.33% higher compared to the previous year.

The Locus Cell Co EV/EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/EBIT
Date
EV/EBIT
Jan 1, 2020
-85,416.85 TWD
Jan 1, 2021
-160.53 TWD
Jan 1, 2022
-58.40 TWD
Jan 1, 2023
-38.32 TWD
Jan 1, 2024
-33.98 TWD
The Locus Cell Co EV/EBIT history
YEAREV/EBITYoY
-33.98-11.33%
-38.32-34.38%
-58.40-63.62%
-160.53-99.81%
-85,416.85—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Locus Cell Co Stock analysis

What does Locus Cell Co do? Locus Cell Co Ltd is a company based in Taipei, Taiwan, operating within the Health Care sector, specifically in the Life Sciences Tools & Services industry. The company has 32 employees and went public on April 28, 2022. Its primary business involves the entrusted development and manufacturing of cell therapy-related products. Locus Cell Co Ltd utilizes a pilot facility compliant with Pharmaceutical Inspection Convention and Pharmaceutical Inspection Co-operation Scheme (PIC/S) good manufacturing practices (GMP). The company provides services including process development and scale-up for cell therapy products, analytical method development and validation, clinical GMP manufacturing for trials, and stability testing. It is anticipated to offer services for various cell therapy applications, such as tissue engineering, CAR-T, induced pluripotent stem cells (iPSCs), and mesenchymal stem cells (MSCs). The company's website is http://www.locus-cell.com/. Locus Cell Co Ltd focuses on contract development and manufacturing organization (CDMO) services for cell therapy products, aiming to support the advancement of innovative therapies through its specialized GMP-compliant facility and technical expertise in cell therapy processes. Locus Cell Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Locus Cell Co stock

EV/EBIT (Enterprise Value to EBIT) of Locus Cell Co is -33.98 in 2024.

EV/EBIT (Enterprise Value to EBIT) of Locus Cell Co changed from -38.32 to -33.98, representing a -11.33% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EV/EBIT (Enterprise Value to EBIT) Locus Cell Co since 2006 – with annual values, charts, and detailed analysis.

The EV/EBIT ratio measures a company's enterprise value relative to its operating earnings. It accounts for debt, making it useful for comparing companies with different capital structures.

EV/EBIT = Enterprise Value / Earnings Before Interest and Taxes

To evaluate EV/EBIT (Enterprise Value to EBIT)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/EBIT (Enterprise Value to EBIT).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/EBIT (Enterprise Value to EBIT)'s Locus Cell Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Locus Cell Co

All Key Metrics — Locus Cell Co